Has the coronavirus created a possible entry for PAR ?

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. If you have not heard of Paradigm BioPharmaceuticals (ASX: PAR) then today is your lucky day. PAR is an Australian BioPharmaceutical company that aims to alleviate the cartilage degradation of […]

PAR on the rise with a strong 6 month growth of 120%

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Paradigm Co (PAR:ASX) has been one of our top performing stocks which we’ve been closely following since we started Youth Investment Group. We first noticed Paradigm bouncing around $1.85 and saw it’s […]

Update: Will Paradigm’s stock price surge continue into 2020?

Why all the excitement in 2019? Paradigm Biopharmaceuticals captivated investors with an impressive 300% rise over 2019. Paradigm aims to alleviate the suffering and cartilage degradation of Osteoarthritis through their repurposed drug Zilosul. PAR’s rapid stock rise was due to the company’s outstanding collection of clinical data on Zilosul. For any Biotech to achieve success, […]